Publications by authors named "F Airoldi"
A multicenter prospective observational study appraising the effectiveness of the Supera stent after subintimal recanalization of femoro-popliteal artery occlusion: The SUPERSUB II study.
Catheter Cardiovasc Interv
May 2024
Article Synopsis
- The Supera stent is a special medical device that helps improve treatments for difficult artery problems in the leg.
- Researchers studied how effective this stent is after a procedure called subintimal angioplasty, which is used to open blocked arteries.
- The results showed that using the Supera stent led to successful outcomes for almost all patients, and it helped them stay healthy over time with fewer medical resources needed.
Background: In patients with acute coronary syndromes (ACS), current guidelines recommend a low-density lipoprotein cholesterol (LDL-C) level < 1.4 mmol/L (<55 mg/dL).
Methods: The JET-LDL is a multicenter, observational, prospective registry created to investigate levels of LDL-C in consecutive patients with ACS undergoing PCI at 35 Italian hospitals, and to report their lipid lowering therapies (LLT).
Background: The prevalence of atrial fibrillation (AF) in end stage kidney disease (ESKD) patients undergoing dialysis is high, however, the high risk of bleeding often hampers with a correct anticoagulation in ESKD patients with AF, despite high thromboembolic risk. Left atrial appendage (LAA) occlusion is a anticoagulation (OAT) for thromboembolism prevention in AF populations with high hemorrhagic risk.
Methods And Results: The purpose of the study was to evaluate the efficacy and safety of LAA occlusion in a cohort of dialysis patients undergoing the procedure (LAA occlusion cohort, = 106), in comparison with two other ESKD cohorts, one taking warfarin (Warfarin cohort, = 114) and the other without anticoagulation therapy (No-OAT cohort, = 148).
Article Synopsis
- - The study focused on reducing Contrast Associated Acute Kidney Injury (CA-AKI) by comparing the effectiveness of CM volume reduction using the DyeVert system versus traditional methods during cardiovascular procedures.
- - Data was collected from 136 patients at high risk for CA-AKI, with results showing that the DyeVert group had significantly lower contrast media volume and a reduced increase in creatinine levels compared to control patients.
- - Findings indicate that using DyeVert not only lowers the risk of CA-AKI (5.1% vs. 16.8%) but also offers a better outcome than conventional hydration strategies.
Results of a prospective observational study of autologous peripheral blood mononuclear cell therapy for no-option critical limb-threatening ischemia and severe diabetic foot ulcers.
Cardiovasc Diabetol
September 2022
Background: Cell therapy with autologous peripheral blood mononuclear cells (PB-MNCs) may help restore limb perfusion in patients with diabetes mellitus and critical limb-threatening ischemia (CLTI) deemed not eligible for revascularization procedures and consequently at risk for major amputation (no-option). Fundamental is to establish its clinical value and to identify candidates with a greater benefit over time. Assessing the frequency of PB circulating angiogenic cells and extracellular vesicles (EVs) may help in guiding candidate selection.
View Article and Find Full Text PDF